

Galit Alter

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6071361/galit-alter-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

324
papers

20,772
citations

74
h-index

137
g-index

362
ext. papers

29,053
ext. citations

15.7
avg, IF

7.07
L-index

#	Paper	IF	Citations
324	Serological Markers of SARS-CoV-2 Reinfection.. <i>MBio</i> , 2022 , e0214121	7.8	1
323	Innovative vaccine approaches-a Keystone Symposia report.. <i>Annals of the New York Academy of Sciences</i> , 2022 ,	6.5	1
322	mRNA-1273 vaccine-induced antibodies maintain Fc effector functions across SARS-CoV-2 variants of concern.. <i>Immunity</i> , 2022 ,	32.3	9
321	Reduction of CD8 T cell functionality but not inhibitory capacity by integrase inhibitors.. <i>Journal of Virology</i> , 2022 , JVI0173021	6.6	0
320	Humoral and cellular immunogenicity of SARS-CoV-2 vaccines in chronic lymphocytic leukemia: a prospective cohort study.. <i>Blood Advances</i> , 2022 ,	7.8	1
319	Dissecting Fc signatures of protection in neonates following maternal influenza vaccination in a placebo-controlled trial.. <i>Cell Reports</i> , 2022 , 38, 110337	10.6	1
318	Durability of Anti-Spike Antibodies in Infants After Maternal COVID-19 Vaccination or Natural Infection.. <i>JAMA - Journal of the American Medical Association</i> , 2022 ,	27.4	10
317	SARS-CoV-2 antibodies protect against reinfection for at least 6 months in a multicentre seroepidemiological workplace cohort.. <i>PLoS Biology</i> , 2022 , 20, e3001531	9.7	0
316	Comprehensive antibody profiling of mRNA vaccination in children. 2022 ,		3
315	Cooperation Between Systemic and Mucosal Antibodies Induced by Virosomal Vaccines Targeting HIV-1 Env: Protection of Indian Rhesus Macaques Against Low-Dose Intravaginal SHIV Challenges.. <i>Frontiers in Immunology</i> , 2022 , 13, 788619	8.4	0
314	Defining the risk of SARS-CoV-2 variants on immune protection.. <i>Nature</i> , 2022 ,	50.4	7
313	Omicron variant Spike-specific antibody binding and Fc activity is preserved in recipients of mRNA or inactivated COVID-19 vaccines.. <i>Science Translational Medicine</i> , 2022 , 14, eabn9243	17.5	5
312	Durability and Cross-Reactivity of SARS-CoV-2 mRNA Vaccine in Adolescent Children.. <i>Vaccines</i> , 2022 , 10,	5.3	2
311	A modified vaccinia Ankara vaccine expressing spike and nucleocapsid protects rhesus macaques against SARS-CoV-2 delta infection.. <i>Science Immunology</i> , 2022 , eabo0226	28	4
310	A homologous or variant booster vaccine after Ad26.COVS immunization enhances SARS-CoV-2-specific immune responses in rhesus macaques.. <i>Science Translational Medicine</i> , 2022 , eabm4996	17.5	1
309	Functional and structural modifications of influenza antibodies during pregnancy.. <i>IScience</i> , 2022 , 25, 104088	6.1	0
308	mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions.. <i>Science Translational Medicine</i> , 2022 , 14, eabm2311	17.5	11

307	Defining Discriminatory Antibody Fingerprints in Active and Latent Tuberculosis.. <i>Frontiers in Immunology</i> , 2022 , 13, 856906	8.4	0
306	Serological testing for SARS-CoV-2 antibodies of employees shows low transmission working in a cancer center.. <i>PLoS ONE</i> , 2022 , 17, e0266791	3.7	0
305	Defining the determinants of protection against SARS-CoV-2 infection and viral control in a dose-down Ad26.CoV2.S vaccine study in nonhuman primates.. <i>PLoS Biology</i> , 2022 , 20, e3001609	9.7	0
304	Upper and lower respiratory tract correlates of protection against respiratory syncytial virus following vaccination of nonhuman primates. <i>Cell Host and Microbe</i> , 2021 ,	23.4	2
303	Preserved Omicron Spike specific antibody binding and Fc-recognition across COVID-19 vaccine platforms. 2021 ,		6
302	Epidemiological and Immunological Features of Obesity and SARS-CoV-2. <i>Viruses</i> , 2021 , 13,	6.2	4
301	Functional convalescent plasma antibodies and pre-infusion titers shape the early severe COVID-19 immune response. <i>Nature Communications</i> , 2021 , 12, 6853	17.4	3
300	COVID-19 mRNA Vaccine Immunogenicity in Immunosuppressed Individuals. <i>Journal of Infectious Diseases</i> , 2021 ,	7	2
299	Robust IgM responses following intravenous vaccination with Bacille Calmette-Guérin associate with prevention of Mycobacterium tuberculosis infection in macaques. <i>Nature Immunology</i> , 2021 , 22, 1515-1523	19.1	7
298	Sequence and vector shapes vaccine induced antibody effector functions in HIV vaccine trials. <i>PLoS Pathogens</i> , 2021 , 17, e1010016	7.6	1
297	Reduced antibody activity against SARS-CoV-2 B.1.617.2 Delta virus in serum of mRNA-vaccinated patients receiving Tumor Necrosis Factor- α inhibitors. <i>Med</i> , 2021 ,	31.7	8
296	Delayed fractional dosing with RTS,S/AS01 improves humoral immunity to malaria via a balance of polyfunctional NANP6- and Pf16-specific antibodies.. <i>Med</i> , 2021 , 2, 1269-1286.e9	31.7	0
295	A particulate saponin/TLR agonist vaccine adjuvant alters lymph flow and modulates adaptive immunity. <i>Science Immunology</i> , 2021 , 6, eabf1152	28	5
294	Longitudinal characterization of circulating neutrophils uncovers distinct phenotypes associated with disease severity in hospitalized COVID-19 patients 2021 ,		5
293	Selective functional antibody transfer into the breastmilk after SARS-CoV-2 infection. <i>Cell Reports</i> , 2021 , 37, 109959	10.6	3
292	COVID-19 mRNA vaccines drive differential antibody Fc-functional profiles in pregnant, lactating, and nonpregnant women. <i>Science Translational Medicine</i> , 2021 , 13, eabi8631	17.5	19
291	Differential Kinetics of Immune Responses Elicited by Covid-19 Vaccines. <i>New England Journal of Medicine</i> , 2021 , 385, 2010-2012	59.2	57
290	Maternal SARS-CoV-2 infection elicits sexually dimorphic placental immune responses. <i>Science Translational Medicine</i> , 2021 , 13, eabi7428	17.5	15

289	Diverse antiviral IgG effector activities are predicted by unique biophysical antibody features. <i>Retrovirology</i> , 2021 , 18, 35	3.6	2
288	Correlates of protection against SARS-CoV-2 in rhesus macaques. <i>Nature</i> , 2021 , 590, 630-634	50.4	498
287	Vi-specific serological correlates of protection for typhoid fever. <i>Journal of Experimental Medicine</i> , 2021 , 218,	16.6	11
286	Vaccination with SARS-CoV-2 Spike Protein and AS03 Adjuvant Induces Rapid Anamnestic Antibodies in the Lung and Protects Against Virus Challenge in Nonhuman Primates 2021 ,		13
285	The multifaceted roles of breast milk antibodies. <i>Cell</i> , 2021 , 184, 1486-1499	56.2	32
284	Functional Antibodies in COVID-19 Convalescent Plasma 2021 ,		4
283	A modified vaccinia Ankara vector-based vaccine protects macaques from SARS-CoV-2 infection, immune pathology, and dysfunction in the lungs. <i>Immunity</i> , 2021 , 54, 542-556.e9	32.3	35
282	Sexually dimorphic placental responses to maternal SARS-CoV-2 infection 2021 ,		3
281	Non-neutralizing Antibodies May Contribute to Suppression of SIVmac239 Viremia in Indian Rhesus Macaques. <i>Frontiers in Immunology</i> , 2021 , 12, 657424	8.4	0
280	COVID-19 vaccine response in pregnant and lactating women: a cohort study 2021 ,		35
279	Persistence of viral RNA in lymph nodes in ART-suppressed SIV/SHIV-infected Rhesus Macaques. <i>Nature Communications</i> , 2021 , 12, 1474	17.4	7
278	A Fc engineering approach to define functional humoral correlates of immunity against Ebola virus. <i>Immunity</i> , 2021 , 54, 815-828.e5	32.3	7
277	Adjuvanting a subunit COVID-19 vaccine to induce protective immunity. <i>Nature</i> , 2021 , 594, 253-258	50.4	92
276	Immunogenicity of the Ad26.COVS Vaccine for COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021 , 325, 1535-1544	27.4	139
275	Viral Rebound Kinetics Correlate with Distinct HIV Antibody Features. <i>MBio</i> , 2021 , 12,	7.8	4
274	Tissues: the unexplored frontier of antibody mediated immunity. <i>Current Opinion in Virology</i> , 2021 , 47, 52-67	7.5	4
273	Viral Load Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2 in Hospitalized Individuals With Coronavirus Disease 2019. <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofab153	1	5
272	Distinct clonal evolution of B-cells in HIV controllers with neutralizing antibody breadth. <i>ELife</i> , 2021 , 10,	8.9	4

271	COVID-19 mRNA vaccines drive differential Fc-functional profiles in pregnant, lactating, and non-pregnant women 2021 ,		11
270	Associations Between Antibody Fc-Mediated Effector Functions and Long-Term Sequelae in Ebola Virus Survivors. <i>Frontiers in Immunology</i> , 2021 , 12, 682120	8.4	3
269	Mining HIV controllers for broad and functional antibodies to recognize and eliminate HIV-infected cells. <i>Cell Reports</i> , 2021 , 35, 109167	10.6	3
268	Antibodies against human endogenous retrovirus K102 envelope activate neutrophils in systemic lupus erythematosus. <i>Journal of Experimental Medicine</i> , 2021 , 218,	16.6	6
267	Early cross-coronavirus reactive signatures of protective humoral immunity against COVID-19 2021 ,		8
266	Protective efficacy of Ad26.COVS against SARS-CoV-2 B.1.351 in macaques. <i>Nature</i> , 2021 , 596, 423-427	10.4	22
265	Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination. <i>Med</i> , 2021 , 2, 701-719.e19	31.7	10
264	SARS-CoV-2 RBD trimer protein adjuvanted with Alum-3M-052 protects from SARS-CoV-2 infection and immune pathology in the lung. <i>Nature Communications</i> , 2021 , 12, 3587	17.4	17
263	Immunogenicity of Ad26.COVS vaccine against SARS-CoV-2 variants in humans. <i>Nature</i> , 2021 , 596, 268-272	30.7	122
262	Comprehensive Data Integration Approach to Assess Immune Responses and Correlates of RTS,S/AS01-Mediated Protection From Malaria Infection in Controlled Human Malaria Infection Trials. <i>Frontiers in Big Data</i> , 2021 , 4, 672460	2.8	1
261	Coordinated Fc-effector and neutralization functions in HIV-infected children define a window of opportunity for HIV vaccination. <i>Aids</i> , 2021 , 35, 1895-1905	3.5	1
260	Memory B cells targeting SARS-CoV-2 spike protein and their dependence on CD4 T cell help. <i>Cell Reports</i> , 2021 , 35, 109320	10.6	17
259	Immune age and biological age as determinants of vaccine responsiveness among elderly populations: the Human Immunomics Initiative research program. <i>European Journal of Epidemiology</i> , 2021 , 36, 753-762	12.1	3
258	Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women. <i>JAMA - Journal of the American Medical Association</i> , 2021 , 325, 2370-2380	27.4	120
257	Multisystem inflammatory syndrome in children is driven by zonulin-dependent loss of gut mucosal barrier. <i>Journal of Clinical Investigation</i> , 2021 , 131,	15.9	46
256	An intranasal vaccine durably protects against SARS-CoV-2 variants in mice. <i>Cell Reports</i> , 2021 , 36, 109452	10.6	25
255	Ebola vaccine-induced protection in nonhuman primates correlates with antibody specificity and Fc-mediated effects. <i>Science Translational Medicine</i> , 2021 , 13,	17.5	6
254	Proteo-Genomic Analysis Identifies Two Major Sites of Vulnerability on Ebolavirus Glycoprotein for Neutralizing Antibodies in Convalescent Human Plasma. <i>Frontiers in Immunology</i> , 2021 , 12, 706757	8.4	0

253	Evaluation of Three Commercial and Two Non-Commercial Immunoassays for the Detection of Prior Infection to SARS-CoV-2. <i>Journal of applied laboratory medicine, The</i> , 2021 , 6, 1561-1570	2	4
252	Adoptive Transfer of Serum Samples From Children With Invasive Staphylococcal Infection and Protection Against Staphylococcus aureus Sepsis. <i>Journal of Infectious Diseases</i> , 2021 , 223, 1222-1231	7	2
251	Liver Fibrosis Index FIB-4 Is Associated With Mortality in COVID-19. <i>Hepatology Communications</i> , 2021 , 5, 434-445	6	12
250	Reply. <i>Journal of Pediatrics</i> , 2021 , 228, 320-323	3.6	
249	COVID-19-neutralizing antibodies predict disease severity and survival. <i>Cell</i> , 2021 , 184, 476-488.e11	56.2	270
248	Collaboration between the Fab and Fc contribute to maximal protection against SARS-CoV-2 in nonhuman primates following NVX-CoV2373 subunit vaccine with Matrix-M μ vaccination 2021 ,		16
247	Antibodies for Human Immunodeficiency Virus-1 Cure Strategies. <i>Journal of Infectious Diseases</i> , 2021 , 223, 22-31	7	4
246	Discrete SARS-CoV-2 antibody titers track with functional humoral stability. <i>Nature Communications</i> , 2021 , 12, 1018	17.4	46
245	Adjuvanting a subunit SARS-CoV-2 nanoparticle vaccine to induce protective immunity in non-human primates 2021 ,		7
244	Collaboration between the Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M μ vaccination 2021 ,		6
243	Compromised SARS-CoV-2-specific placental antibody transfer. <i>Cell</i> , 2021 , 184, 628-642.e10	56.2	72
242	Humoral signatures of protective and pathological SARS-CoV-2 infection in children. <i>Nature Medicine</i> , 2021 , 27, 454-462	50.5	50
241	Comorbid illnesses are associated with altered adaptive immune responses to SARS-CoV-2. <i>JCI Insight</i> , 2021 , 6,	9.9	11
240	Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates. <i>Science Translational Medicine</i> , 2021 , 13,	17.5	17
239	Antibody Subclass and Glycosylation Shift Following Effective TB Treatment. <i>Frontiers in Immunology</i> , 2021 , 12, 679973	8.4	3
238	Pan-protective anti-alphavirus human antibodies target a conserved E1 protein epitope. <i>Cell</i> , 2021 , 184, 4414-4429.e19	56.2	7
237	HIV Antibody Profiles in HIV Controllers and Persons With Treatment-Induced Viral Suppression. <i>Frontiers in Immunology</i> , 2021 , 12, 740395	8.4	0
236	The autoimmune signature of hyperinflammatory multisystem inflammatory syndrome in children. <i>Journal of Clinical Investigation</i> , 2021 , 131,	15.9	20

235	Therapeutic alphavirus cross-reactive E1 human antibodies inhibit viral egress. <i>Cell</i> , 2021 , 184, 4430-4446.e22	4
234	Subtle immunological differences in mRNA-1273 and BNT162b2 COVID-19 vaccine induced Fc-functional profiles 2021 ,	8
233	A Specific IgG3 Signature of Recurrent Tuberculosis. <i>Frontiers in Immunology</i> , 2021 , 12, 729186	8.4 2
232	Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination. <i>Cell Reports Medicine</i> , 2021 , 2, 100405	18 34
231	Coronavirus disease 2019 vaccine response in pregnant and lactating women: a cohort study. <i>American Journal of Obstetrics and Gynecology</i> , 2021 , 225, 303.e1-303.e17	6.4 185
230	Early cross-coronavirus reactive signatures of humoral immunity against COVID-19. <i>Science Immunology</i> , 2021 , 6, eabj2901	28 22
229	Dissecting strategies to tune the therapeutic potential of SARS-CoV-2-specific monoclonal antibody CR3022. <i>JCI Insight</i> , 2021 , 6,	9.9 22
228	Neutrophil Profiles of Pediatric COVID-19 and Multisystem Inflammatory Syndrome in Children. 2021 ,	5
227	Quick COVID-19 Healers Sustain Anti-SARS-CoV-2 Antibody Production. <i>Cell</i> , 2020 , 183, 1496-1507.e16	56.2 127
226	Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 Mortality. <i>Cell</i> , 2020 , 183, 1508-1516.e12	56.2 134
225	SARS-CoV-2 infection protects against rechallenge in rhesus macaques. <i>Science</i> , 2020 , 369, 812-817	33.3 592
224	DNA vaccine protection against SARS-CoV-2 in rhesus macaques. <i>Science</i> , 2020 , 369, 806-811	33.3 748
223	Survivors of Ebola Virus Disease Develop Polyfunctional Antibody Responses. <i>Journal of Infectious Diseases</i> , 2020 , 221, 156-161	7 19
222	Co-immunization of DNA and Protein in the Same Anatomical Sites Induces Superior Protective Immune Responses against SHIV Challenge. <i>Cell Reports</i> , 2020 , 31, 107624	10.6 19
221	Dissecting antibody-mediated protection against SARS-CoV-2. <i>Nature Reviews Immunology</i> , 2020 , 20, 392-394	36.5 132
220	Distinct neutralizing antibody correlates of protection among related Zika virus vaccines identify a role for antibody quality. <i>Science Translational Medicine</i> , 2020 , 12,	17.5 11
219	Distinct Human NK Cell Phenotypes and Functional Responses to in Adults From TB Endemic and Non-endemic Regions. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020 , 10, 120	5.9 13
218	Hinge length contributes to the phagocytic activity of HIV-specific IgG1 and IgG3 antibodies. <i>PLoS Pathogens</i> , 2020 , 16, e1008083	7.6 20

217	Understanding the role of antibody glycosylation through the lens of severe viral and bacterial diseases. <i>Glycobiology</i> , 2020 , 30, 241-253	5.8	39
216	Antibody Fc Glycosylation Discriminates Between Latent and Active Tuberculosis. <i>Journal of Infectious Diseases</i> , 2020 , 222, 2093-2102	7	25
215	Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17-22). <i>Lancet HIV,the</i> , 2020 , 7, e410-e421	7.8	11
214	Maternal determinants of infant immunity: Implications for effective immunization and maternal-child health. <i>Vaccine</i> , 2020 , 38, 4491-4494	4.1	1
213	Analysis of a Therapeutic Antibody Cocktail Reveals Determinants for Cooperative and Broad Ebola virus Neutralization. <i>Immunity</i> , 2020 , 52, 388-403.e12	32.3	42
212	Non-neutralizing Antibodies from a Marburg Infection Survivor Mediate Protection by Fc-Effector Functions and by Enhancing Efficacy of Other Antibodies. <i>Cell Host and Microbe</i> , 2020 , 27, 976-991.e11	23.4	29
211	HIV Is Associated with Modified Humoral Immune Responses in the Setting of HIV/TB Coinfection. <i>MSphere</i> , 2020 , 5,	5	5
210	Distinct Immunoglobulin Fc Glycosylation Patterns Are Associated with Disease Nonprogression and Broadly Neutralizing Antibody Responses in Children with HIV Infection. <i>MSphere</i> , 2020 , 5,	5	2
209	Protein-based, but not viral vector alone, HIV vaccine boosting drives an IgG1-biased polyfunctional humoral immune response. <i>JCI Insight</i> , 2020 , 5,	9.9	4
208	IgG3 collaborates with IgG1 and IgA to recruit effector function in RV144 vaccinees. <i>JCI Insight</i> , 2020 , 5,	9.9	1
207	Selective induction of antibody effector functional responses using MF59-adjuvanted vaccination. <i>Journal of Clinical Investigation</i> , 2020 , 130, 662-672	15.9	25
206	RV144 HIV-1 vaccination impacts post-infection antibody responses. <i>PLoS Pathogens</i> , 2020 , 16, e1009107.6	4.6	3
205	Ultra-Sensitive High-Resolution Profiling of Anti-SARS-CoV-2 Antibodies for Detecting Early Seroconversion in COVID-19 Patients 2020 ,		18
204	Evaluation of two commercial and two non-commercial immunoassays for the detection of prior infection to SARS-CoV-2 2020 ,		7
203	Dynamics and significance of the antibody response to SARS-CoV-2 infection 2020 ,		60
202	Rapid Mix and readPassay for scalable detection of SARS-CoV-2 antibodies in patient plasma 2020 ,		3
201	COVID-19 neutralizing antibodies predict disease severity and survival 2020 ,		10
200	Epidemiological and immunological features of obesity and SARS-CoV-2 2020 ,		3

199	T cell and antibody functional correlates of severe COVID-19 2020 ,		6
198	Passive Transfer of Vaccine-Elicited Antibodies Protects against SIV in Rhesus Macaques. <i>Cell</i> , 2020 , 183, 185-196.e14	56.2	11
197	Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity. <i>Science</i> , 2020 , 370,	33.3	289
196	Antibodies targeting epitopes on the cell-surface form of NS1 protect against Zika virus infection during pregnancy. <i>Nature Communications</i> , 2020 , 11, 5278	17.4	16
195	Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. <i>Science Immunology</i> , 2020 , 5,	28	353
194	Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. <i>Nature</i> , 2020 , 586, 583-588	50.4	550
193	Mining for humoral correlates of HIV control and latent reservoir size. <i>PLoS Pathogens</i> , 2020 , 16, e1008868	6.8	5
192	An observational study identifying highly tuberculosis-exposed, HIV-1-positive but persistently TB, tuberculin and IGRA negative persons with M. tuberculosis specific antibodies in Cape Town, South Africa. <i>EBioMedicine</i> , 2020 , 61, 103053	8.8	8
191	Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19. <i>Cell</i> , 2020 , 183, 143-167.e13	16.7	131
190	Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host. <i>New England Journal of Medicine</i> , 2020 , 383, 2291-2293	59.2	533
189	Tracking the Trajectory of Functional Humoral Immune Responses Following Acute HIV Infection. <i>Frontiers in Immunology</i> , 2020 , 11, 1744	8.4	1
188	Dissecting the antibody-OME: past, present, and future. <i>Current Opinion in Immunology</i> , 2020 , 65, 89-96	7.8	4
187	Mapping functional humoral correlates of protection against malaria challenge following RTS,S/AS01 vaccination. <i>Science Translational Medicine</i> , 2020 , 12,	17.5	46
186	Integrated pipeline for the accelerated discovery of antiviral antibody therapeutics. <i>Nature Biomedical Engineering</i> , 2020 , 4, 1030-1043	19	21
185	Distinct Early Serological Signatures Track with SARS-CoV-2 Survival. <i>Immunity</i> , 2020 , 53, 524-532.e4	32.3	219
184	SARS-CoV-2-specific ELISA development. <i>Journal of Immunological Methods</i> , 2020 , 484-485, 112832	2.5	45
183	Mucosal Therapy of Multi-Drug Resistant Tuberculosis With IgA and Interferon- γ <i>Frontiers in Immunology</i> , 2020 , 11, 582833	8.4	4
182	SARS-CoV-2 viral load is associated with increased disease severity and mortality. <i>Nature Communications</i> , 2020 , 11, 5493	17.4	360

181	Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters. <i>Nature Medicine</i> , 2020 , 26, 1694-1700	50.5	176
180	Evolution of Early SARS-CoV-2 and Cross-Coronavirus Immunity. <i>MSphere</i> , 2020 , 5,	5	28
179	Modified vaccinia Ankara vaccine expressing Marburg virus-like particles protects guinea pigs from lethal Marburg virus infection. <i>Npj Vaccines</i> , 2020 , 5, 78	9.5	4
178	Ultrasensitive high-resolution profiling of early seroconversion in patients with COVID-19. <i>Nature Biomedical Engineering</i> , 2020 , 4, 1180-1187	19	70
177	High Seroprevalence of Anti-SARS-CoV-2 Antibodies in Chelsea, Massachusetts. <i>Journal of Infectious Diseases</i> , 2020 , 222, 1955-1959	7	39
176	Pediatric Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Clinical Presentation, Infectivity, and Immune Responses. <i>Journal of Pediatrics</i> , 2020 , 227, 45-52.e5	3.6	192
175	Targeting HIV Env immunogens to B cell follicles in nonhuman primates through immune complex or protein nanoparticle formulations. <i>Npj Vaccines</i> , 2020 , 5, 72	9.5	20
174	HIV Antibody Fc N-Linked Glycosylation Is Associated with Viral Rebound. <i>Cell Reports</i> , 2020 , 33, 108502	10.6	10
173	Assessment of Maternal and Neonatal SARS-CoV-2 Viral Load, Transplacental Antibody Transfer, and Placental Pathology in Pregnancies During the COVID-19 Pandemic. <i>JAMA Network Open</i> , 2020 , 3, e2030455	10.4	149
172	A vaccine-induced gene expression signature correlates with protection against SIV and HIV in multiple trials. <i>Science Translational Medicine</i> , 2019 , 11,	17.5	15
171	A Molecular Signature in Blood Reveals a Role for p53 in Regulating Malaria-Induced Inflammation. <i>Immunity</i> , 2019 , 51, 750-765.e10	32.3	31
170	A Sample-Sparing Multiplexed ADCP Assay. <i>Frontiers in Immunology</i> , 2019 , 10, 1851	8.4	17
169	Multi-isotype Glycoproteomic Characterization of Serum Antibody Heavy Chains Reveals Isotype- and Subclass-Specific -Glycosylation Profiles. <i>Molecular and Cellular Proteomics</i> , 2019 , 18, 686-703	7.6	27
168	Antibody Fab-Fc properties outperform titer in predictive models of SIV vaccine-induced protection. <i>Molecular Systems Biology</i> , 2019 , 15, e8747	12.2	10
167	A versatile high-throughput assay to characterize antibody-mediated neutrophil phagocytosis. <i>Journal of Immunological Methods</i> , 2019 , 471, 46-56	2.5	63
166	Outflanking immunodominance to target subdominant broadly neutralizing epitopes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 , 116, 13474-13479	11.5	40
165	A Case for Antibodies as Mechanistic Correlates of Immunity in Tuberculosis. <i>Frontiers in Immunology</i> , 2019 , 10, 996	8.4	21
164	Fc Glycan-Mediated Regulation of Placental Antibody Transfer. <i>Cell</i> , 2019 , 178, 202-215.e14	56.2	81

163	IFN-Independent immune markers of Mycobacterium tuberculosis exposure. <i>Nature Medicine</i> , 2019 , 25, 977-987	50.5	104
162	Expansion of Stem Cell-Like CD4 Memory T Cells during Acute HIV-1 Infection Is Linked to Rapid Disease Progression. <i>Journal of Virology</i> , 2019 , 93,	6.6	5
161	The Antibodiome-Mapping the Humoral Immune Response to HIV. <i>Current HIV/AIDS Reports</i> , 2019 , 16, 169-179	5.9	6
160	Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence features. <i>PLoS Computational Biology</i> , 2019 , 15, e1006952	5	13
159	Extra-Neutralizing FcR-Mediated Antibody Functions for a Universal Influenza Vaccine. <i>Frontiers in Immunology</i> , 2019 , 10, 440	8.4	29
158	Optimal therapeutic activity of monoclonal antibodies against chikungunya virus requires Fc-FcR interaction on monocytes. <i>Science Immunology</i> , 2019 , 4,	28	36
157	A high-throughput, bead-based, antigen-specific assay to assess the ability of antibodies to induce complement activation. <i>Journal of Immunological Methods</i> , 2019 , 473, 112630	2.5	70
156	Neutralizing antibodies against Mayaro virus require Fc effector functions for protective activity. <i>Journal of Experimental Medicine</i> , 2019 , 216, 2282-2301	16.6	25
155	Fc Characteristics Mediate Selective Placental Transfer of IgG in HIV-Infected Women. <i>Cell</i> , 2019 , 178, 190-201.e11	56.2	59
154	Predicting the broadly neutralizing antibody susceptibility of the HIV reservoir. <i>JCI Insight</i> , 2019 , 4,	9.9	11
153	ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type. <i>PLoS Pathogens</i> , 2019 , 15, e1008121	7.6	7
152	Initiation of Antiretroviral Therapy Before Pregnancy Reduces the Risk of Infection-related Hospitalization in Human Immunodeficiency Virus-exposed Uninfected Infants Born in a High-income Country. <i>Clinical Infectious Diseases</i> , 2019 , 68, 1193-1203	11.6	29
151	Sex differences in vaccine-induced humoral immunity. <i>Seminars in Immunopathology</i> , 2019 , 41, 239-249	12	125
150	Reply to Slogrove et al. <i>Clinical Infectious Diseases</i> , 2019 , 68, 2158	11.6	2
149	Development of a Human Antibody Cocktail that Deploys Multiple Functions to Confer Pan-Ebolavirus Protection. <i>Cell Host and Microbe</i> , 2019 , 25, 39-48.e5	23.4	59
148	A Two-Antibody Pan-Ebolavirus Cocktail Confers Broad Therapeutic Protection in Ferrets and Nonhuman Primates. <i>Cell Host and Microbe</i> , 2019 , 25, 49-58.e5	23.4	55
147	Sex-Based Differences in Human Immunodeficiency Virus Type 1 Reservoir Activity and Residual Immune Activation. <i>Journal of Infectious Diseases</i> , 2019 , 219, 1084-1094	7	38
146	Antibody-Mediated Protective Mechanisms Induced by a Trivalent Parainfluenza Virus-Vectored Ebolavirus Vaccine. <i>Journal of Virology</i> , 2019 , 93,	6.6	6

145	Viral control in chronic HIV-1 subtype C infection is associated with enrichment of p24 IgG1 with Fc effector activity. <i>Aids</i> , 2018 , 32, 1207-1217	3.5	16
144	High-resolution definition of humoral immune response correlates of effective immunity against HIV. <i>Molecular Systems Biology</i> , 2018 , 14, e7881	12.2	25
143	First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector. <i>Journal of Infectious Diseases</i> , 2018 , 218, 633-644	7	23
142	Temporal variation in HIV-specific IgG subclass antibodies during acute infection differentiates spontaneous controllers from chronic progressors. <i>Aids</i> , 2018 , 32, 443-450	3.5	25
141	Prevention of tuberculosis in rhesus macaques by a cytomegalovirus-based vaccine. <i>Nature Medicine</i> , 2018 , 24, 130-143	50.5	141
140	Enrichment of high affinity subclasses and glycoforms from serum-derived IgG using FcRs as affinity ligands. <i>Biotechnology and Bioengineering</i> , 2018 , 115, 1265-1278	4.9	5
139	The Marburgvirus-Neutralizing Human Monoclonal Antibody MR191 Targets a Conserved Site to Block Virus Receptor Binding. <i>Cell Host and Microbe</i> , 2018 , 23, 101-109.e4	23.4	25
138	Optimization and qualification of an Fc Array assay for assessments of antibodies against HIV-1/SIV. <i>Journal of Immunological Methods</i> , 2018 , 455, 24-33	2.5	23
137	Beyond binding: antibody effector functions in infectious diseases. <i>Nature Reviews Immunology</i> , 2018 , 18, 46-61	36.5	280
136	Control of Heterologous Simian Immunodeficiency Virus SIV Infection by DNA and Protein Coimmunization Regimens Combined with Different Toll-Like-Receptor-4-Based Adjuvants in Macaques. <i>Journal of Virology</i> , 2018 , 92,	6.6	27
135	Analysis of Complement-Mediated Lysis of Simian Immunodeficiency Virus (SIV) and SIV-Infected Cells Reveals Sex Differences in Vaccine-Induced Immune Responses in Rhesus Macaques. <i>Journal of Virology</i> , 2018 , 92,	6.6	19
134	Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). <i>Lancet, The</i> , 2018 , 392, 232-243	40	170
133	Fully Human Immunoglobulin G From Transchromosomal Bovines Treats Nonhuman Primates Infected With Ebola Virus Makona Isolate. <i>Journal of Infectious Diseases</i> , 2018 , 218, S636-S648	7	13
132	Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein. <i>Immunity</i> , 2018 , 49, 363-374.e10	32.3	47
131	Immune Correlate-Guided HIV Vaccine Design. <i>Cell Host and Microbe</i> , 2018 , 24, 25-33	23.4	34
130	Antigen-specific antibody Fc glycosylation enhances humoral immunity via the recruitment of complement. <i>Science Immunology</i> , 2018 , 3,	28	41
129	Exploiting glycan topography for computational design of Env glycoprotein antigenicity. <i>PLoS Computational Biology</i> , 2018 , 14, e1006093	5	14
128	Neonate-omics: Charting the Unknown Immune Response in Early Life. <i>Cell</i> , 2018 , 174, 1051-1053	56.2	8

127	Asymmetric antiviral effects of ebolavirus antibodies targeting glycoprotein stem and glycan cap. <i>PLoS Pathogens</i> , 2018 , 14, e1007204	7.6	13
126	A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus. <i>Cell Host and Microbe</i> , 2018 , 24, 221-233.e5	23.4	121
125	Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection. <i>Cell</i> , 2018 , 174, 938-952.e13	56.2	126
124	Antibody glycosylation in inflammation, disease and vaccination. <i>Seminars in Immunology</i> , 2018 , 39, 102-110	10.7	74
123	HIV-specific Fc effector function early in infection predicts the development of broadly neutralizing antibodies. <i>PLoS Pathogens</i> , 2018 , 14, e1006987	7.6	49
122	Immunological mechanisms of human resistance to persistent Mycobacterium tuberculosis infection. <i>Nature Reviews Immunology</i> , 2018 , 18, 575-589	36.5	118
121	ADCC-Mediated CD56 NK Cell Responses Are Associated with Early HBsAg Clearance in Acute HBV Infection. <i>Pathogens and Immunity</i> , 2018 , 3, 2-18	4.9	16
120	Vectored delivery of anti-SIV envelope targeting mAb via AAV8 protects rhesus macaques from repeated limiting dose intrarectal swarm SIVsmE660 challenge. <i>PLoS Pathogens</i> , 2018 , 14, e1007395	7.6	19
119	Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys. <i>Nature</i> , 2018 , 563, 360-364	50.4	155
118	Antibody-mediated protection against Ebola virus. <i>Nature Immunology</i> , 2018 , 19, 1169-1178	19.1	90
117	Modulation of Vaccine-Induced CD4 T Cell Functional Profiles by Changes in Components of HIV Vaccine Regimens in Humans. <i>Journal of Virology</i> , 2018 , 92,	6.6	5
116	The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial. <i>Npj Vaccines</i> , 2018 , 3, 34	9.5	77
115	Route of immunization defines multiple mechanisms of vaccine-mediated protection against SIV. <i>Nature Medicine</i> , 2018 , 24, 1590-1598	50.5	73
114	Systems serology for evaluation of HIV vaccine trials. <i>Immunological Reviews</i> , 2017 , 275, 262-270	11.3	47
113	Multiplexed Fc array for evaluation of antigen-specific antibody effector profiles. <i>Journal of Immunological Methods</i> , 2017 , 443, 33-44	2.5	85
112	Preservation of Peripheral T Follicular Helper Cell Function in HIV Controllers. <i>Journal of Virology</i> , 2017 , 91,	6.6	21
111	The HIV-1 Glycan Shield: Strategically Placed Kinks in the Armor Improve Antigen Design. <i>Cell Reports</i> , 2017 , 19, 669-670	10.6	5
110	Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge. <i>Nature Communications</i> , 2017 , 8, 15711	17.4	94

109	The Immunoregulatory Roles of Antibody Glycosylation. <i>Trends in Immunology</i> , 2017 , 38, 358-372	14.4	162
108	Transfer of maternal immunity and programming of the newborn immune system. <i>Seminars in Immunopathology</i> , 2017 , 39, 605-613	12	67
107	Systems serology: profiling vaccine induced humoral immunity against HIV. <i>Retrovirology</i> , 2017 , 14, 57	3.6	35
106	Differential Inhibitory Receptor Expression on T Cells Delineates Functional Capacities in Chronic Viral Infection. <i>Journal of Virology</i> , 2017 , 91,	6.6	25
105	Opportunities to exploit antibody glycosylation in vaccination. <i>Future Virology</i> , 2017 , 12, 325-328	2.4	2
104	Virus-driven Inflammation Is Associated With the Development of bNAbs in Spontaneous Controllers of HIV. <i>Clinical Infectious Diseases</i> , 2017 , 64, 1098-1104	11.6	25
103	Innate transcriptional effects by adjuvants on the magnitude, quality, and durability of HIV envelope responses in NHPs. <i>Blood Advances</i> , 2017 , 1, 2329-2342	7.8	57
102	Plasma CXCL13 but Not B Cell Frequencies in Acute HIV Infection Predicts Emergence of Cross-Neutralizing Antibodies. <i>Frontiers in Immunology</i> , 2017 , 8, 1104	8.4	23
101	Immune Responses to Viral Infection 2016 , 321-350		
100	IgG Binding Characteristics of Rhesus Macaque FcR. <i>Journal of Immunology</i> , 2016 , 197, 2936-47	5.3	32
99	A Functional Role for Antibodies in Tuberculosis. <i>Cell</i> , 2016 , 167, 433-443.e14	56.2	306
98	Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys. <i>Nature</i> , 2016 , 540, 284-287	50.4	183
97	Modulating Antibody Functionality in Infectious Disease and Vaccination. <i>Trends in Molecular Medicine</i> , 2016 , 22, 969-982	11.5	54
96	Multiplexed Affinity-Based Separation of Proteins and Cells Using Inertial Microfluidics. <i>Scientific Reports</i> , 2016 , 6, 23589	4.9	45
95	Broadly Neutralizing Antibodies: Magic Bullets against HIV?. <i>Immunity</i> , 2016 , 44, 1253-4	32.3	3
94	Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition. <i>Nature Medicine</i> , 2016 , 22, 762-70	50.5	147
93	NK Cells in HIV Disease. <i>Current HIV/AIDS Reports</i> , 2016 , 13, 85-94	5.9	82
92	Circulating HIV-Specific Interleukin-21(+)CD4(+) T Cells Represent Peripheral Tfh Cells with Antigen-Dependent Helper Functions. <i>Immunity</i> , 2016 , 44, 167-178	32.3	78

91	A Drug-Free Zone--Lymph Nodes as a Safe Haven for HIV. <i>Cell Host and Microbe</i> , 2016 , 19, 275-6	23.4	15
90	Enhanced binding of antibodies generated during chronic HIV infection to mucus component MUC16. <i>Mucosal Immunology</i> , 2016 , 9, 1549-1558	9.2	41
89	Pan-ebolavirus and Pan-filovirus Mouse Monoclonal Antibodies: Protection against Ebola and Sudan Viruses. <i>Journal of Virology</i> , 2016 , 90, 266-78	6.6	78
88	Broadly Neutralizing Antibodies Against HIV: New Insights to Inform Vaccine Design. <i>Annual Review of Medicine</i> , 2016 , 67, 185-200	17.4	30
87	Antigen-Specific Antibody Glycosylation Is Regulated via Vaccination. <i>PLoS Pathogens</i> , 2016 , 12, e10054566	5.6	88
86	Polyfunctional HIV-Specific Antibody Responses Are Associated with Spontaneous HIV Control. <i>PLoS Pathogens</i> , 2016 , 12, e1005315	7.6	167
85	Diversity of Antiviral IgG Effector Activities Observed in HIV-Infected and Vaccinated Subjects. <i>Journal of Immunology</i> , 2016 , 197, 4603-4612	5.3	37
84	HLA-C levels impact natural killer cell subset distribution and function. <i>Human Immunology</i> , 2016 , 77, 1147-1153	2.3	15
83	Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys. <i>Science</i> , 2016 , 353, 1129-32	33.3	386
82	A method for high-throughput, sensitive analysis of IgG Fc and Fab glycosylation by capillary electrophoresis. <i>Journal of Immunological Methods</i> , 2015 , 417, 34-44	2.5	64
81	Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys. <i>Science</i> , 2015 , 349, 320-4	33.3	236
80	Machine learning methods enable predictive modeling of antibody feature: function relationships in RV144 vaccinees. <i>PLoS Computational Biology</i> , 2015 , 11, e1004185	5	32
79	Cooperativity of HIV-Specific Cytolytic CD4 T Cells and CD8 T Cells in Control of HIV Viremia. <i>Journal of Virology</i> , 2015 , 89, 7494-505	6.6	56
78	HIV-1 single-stranded RNA induces CXCL13 secretion in human monocytes via TLR7 activation and plasmacytoid dendritic cell-derived type I IFN. <i>Journal of Immunology</i> , 2015 , 194, 2769-75	5.3	32
77	Dissecting Polyclonal Vaccine-Induced Humoral Immunity against HIV Using Systems Serology. <i>Cell</i> , 2015 , 163, 988-98	56.2	230
76	Microscale purification of antigen-specific antibodies. <i>Journal of Immunological Methods</i> , 2015 , 425, 27-365	5	15
75	Exploring the potential of monoclonal antibody therapeutics for HIV-1 eradication. <i>AIDS Research and Human Retroviruses</i> , 2015 , 31, 13-24	1.6	44
74	Prospects for engineering HIV-specific antibodies for enhanced effector function and half-life. <i>Current Opinion in HIV and AIDS</i> , 2015 , 10, 160-9	4.2	19

73	Modest attenuation of HIV-1 Vpu alleles derived from elite controller plasma. <i>PLoS ONE</i> , 2015 , 10, e0120434	9.7	11
72	Selection of an HLA-C*03:04-Restricted HIV-1 p24 Gag Sequence Variant Is Associated with Viral Escape from KIR2DL3+ Natural Killer Cells: Data from an Observational Cohort in South Africa. <i>PLoS Medicine</i> , 2015 , 12, e1001900; discussion e1001900	11.6	49
71	Beyond adjuvants: Antagonizing inflammation to enhance vaccine immunity. <i>Vaccine</i> , 2015 , 33 Suppl 2, B55-9	4.1	20
70	CD39 Expression Identifies Terminally Exhausted CD8+ T Cells. <i>PLoS Pathogens</i> , 2015 , 11, e1005177	7.6	183
69	Emergence of individual HIV-specific CD8 T cell responses during primary HIV-1 infection can determine long-term disease outcome. <i>Journal of Virology</i> , 2014 , 88, 12793-801	6.6	27
68	Early preservation of CXCR5+ PD-1+ helper T cells and B cell activation predict the breadth of neutralizing antibody responses in chronic HIV-1 infection. <i>Journal of Virology</i> , 2014 , 88, 13310-21	6.6	63
67	An antibody tag-team: driving neutralization through escape. <i>Trends in Immunology</i> , 2014 , 35, 403-5	14.4	
66	KIR2DL3+NKG2A? natural killer cells are associated with protection from productive hepatitis C virus infection in people who inject drugs. <i>Journal of Hepatology</i> , 2014 , 61, 475-81	13.4	28
65	Chronic HCV infection affects the NK cell phenotype in the blood more than in the liver. <i>PLoS ONE</i> , 2014 , 9, e105950	3.7	13
64	Highly parallel characterization of IgG Fc binding interactions. <i>MAbs</i> , 2014 , 6, 915-27	6.6	48
63	Divergent antibody subclass and specificity profiles but not protective HLA-B alleles are associated with variable antibody effector function among HIV-1 controllers. <i>Journal of Virology</i> , 2014 , 88, 2799-809	6.6	40
62	Dissecting the antibody constant region protective immune parameters in HIV infection. <i>Future Virology</i> , 2014 , 9, 397-414	2.4	8
61	Modulation of RAS Pathways as a Biomarker of Protection against HIV and as a Means to Improve Vaccine Efficacy. <i>AIDS Research and Human Retroviruses</i> , 2014 , 30, A99-A99	1.6	2
60	Independent evolution of Fc- and Fab-mediated HIV-1-specific antiviral antibody activity following acute infection. <i>European Journal of Immunology</i> , 2014 , 44, 2925-37	6.1	41
59	Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines. <i>Science Translational Medicine</i> , 2014 , 6, 228ra38	17.5	290
58	Identification of antibody glycosylation structures that predict monoclonal antibody Fc-effector function. <i>Aids</i> , 2014 , 28, 2523-30	3.5	84
57	Effect of human immunodeficiency virus infection on plasma bactericidal activity against <i>Salmonella enterica</i> serovar Typhimurium. <i>Vaccine Journal</i> , 2014 , 21, 1437-42		6
56	Lack of protection following passive transfer of polyclonal highly functional low-dose non-neutralizing antibodies. <i>PLoS ONE</i> , 2014 , 9, e97229	3.7	50

55	KIR2DS4 promotes HIV-1 pathogenesis: new evidence from analyses of immunogenetic data and natural killer cell function. <i>PLoS ONE</i> , 2014 , 9, e99353	3.7	22
54	Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. <i>Cell</i> , 2013 , 155, 531-9	56.2	268
53	Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001). <i>Journal of Infectious Diseases</i> , 2013 , 207, 248-56	7	86
52	Enhanced phagocytic activity of HIV-specific antibodies correlates with natural production of immunoglobulins with skewed affinity for FcR2a and FcR2b. <i>Journal of Virology</i> , 2013 , 87, 5468-76	6.6	72
51	Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity. <i>Journal of Clinical Investigation</i> , 2013 , 123, 2183-92	15.9	233
50	Opportunities to exploit non-neutralizing HIV-specific antibody activity. <i>Current HIV Research</i> , 2013 , 11, 365-77	1.3	28
49	Emerging concepts on the role of innate immunity in the prevention and control of HIV infection. <i>Annual Review of Medicine</i> , 2012 , 63, 113-30	17.4	48
48	High-throughput, multiplexed IgG subclassing of antigen-specific antibodies from clinical samples. <i>Journal of Immunological Methods</i> , 2012 , 386, 117-23	2.5	132
47	Innate immune control of HIV. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2012 , 2, a007070	5.4	50
46	A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcR3a-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques. <i>Journal of Virology</i> , 2012 , 86, 6189-96	6.6	96
45	A 17q12 allele is associated with altered NK cell subsets and function. <i>Journal of Immunology</i> , 2012 , 188, 3315-22	5.3	21
44	KIR/HLA: genetic clues for a role of NK cells in the control of HIV. <i>Advances in Experimental Medicine and Biology</i> , 2011 , 780, 27-36	3.6	8
43	HIV-1 adaptation to NK-cell-mediated immune pressure. <i>Nature</i> , 2011 , 476, 96-100	50.4	251
42	Mutiny or scrutiny: NK cell modulation of DC function in HIV-1 infection. <i>Trends in Immunology</i> , 2011 , 32, 219-24	14.4	23
41	Reduced frequencies of NKp30+NKp46+, CD161+, and NKG2D+ NK cells in acute HCV infection may predict viral clearance. <i>Journal of Hepatology</i> , 2011 , 55, 278-88	13.4	87
40	Copy number variation of KIR genes influences HIV-1 control. <i>PLoS Biology</i> , 2011 , 9, e1001208	9.7	111
39	Natural killer cells in spontaneous control of HIV infection. <i>Current Opinion in HIV and AIDS</i> , 2011 , 6, 208-13	4.3	20
38	Determining the phagocytic activity of clinical antibody samples. <i>Journal of Visualized Experiments</i> , 2011 , e3588	1.6	19

37	A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. <i>Journal of Immunological Methods</i> , 2011 , 366, 8-19	2.5	266
36	Decreased Fc receptor expression on innate immune cells is associated with impaired antibody-mediated cellular phagocytic activity in chronically HIV-1 infected individuals. <i>Virology</i> , 2011 , 415, 160-7	3.6	60
35	Early viral replication in lymph nodes provides HIV with a means by which to escape NK-cell-mediated control. <i>European Journal of Immunology</i> , 2011 , 41, 2729-40	6.1	19
34	Characteristics of the earliest cross-neutralizing antibody response to HIV-1. <i>PLoS Pathogens</i> , 2011 , 7, e1001251	7.6	241
33	KIR polymorphisms modulate peptide-dependent binding to an MHC class I ligand with a Bw6 motif. <i>PLoS Pathogens</i> , 2011 , 7, e1001316	7.6	50
32	The humoral response to HIV-1: new insights, renewed focus. <i>Journal of Infectious Diseases</i> , 2010 , 202 Suppl 2, S315-22	7	38
31	IL-10 induces aberrant deletion of dendritic cells by natural killer cells in the context of HIV infection. <i>Journal of Clinical Investigation</i> , 2010 , 120, 1905-13	15.9	64
30	HLA class I subtype-dependent expansion of KIR3DS1+ and KIR3DL1+ NK cells during acute human immunodeficiency virus type 1 infection. <i>Journal of Virology</i> , 2009 , 83, 6798-805	6.6	149
29	Matrix metalloprotease inhibitors restore impaired NK cell-mediated antibody-dependent cellular cytotoxicity in human immunodeficiency virus type 1 infection. <i>Journal of Virology</i> , 2009 , 83, 8705-12	6.6	84
28	Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1. <i>Nature Medicine</i> , 2009 , 15, 955-9	50.5	412
27	Ligand-independent exhaustion of killer immunoglobulin-like receptor-positive CD8+ T cells in human immunodeficiency virus type 1 infection. <i>Journal of Virology</i> , 2008 , 82, 9668-77	6.6	27
26	Upregulation of PD-L1 on monocytes and dendritic cells by HIV-1 derived TLR ligands. <i>Aids</i> , 2008 , 22, 655-8	3.5	72
25	Antigen load and viral sequence diversification determine the functional profile of HIV-1-specific CD8+ T cells. <i>PLoS Medicine</i> , 2008 , 5, e100	11.6	181
24	Single-stranded RNA derived from HIV-1 serves as a potent activator of NK cells. <i>Journal of Immunology</i> , 2007 , 178, 7658-66	5.3	87
23	Recognition of a defined region within p24 gag by CD8+ T cells during primary human immunodeficiency virus type 1 infection in individuals expressing protective HLA class I alleles. <i>Journal of Virology</i> , 2007 , 81, 7725-31	6.6	106
22	Evolution of innate and adaptive effector cell functions during acute HIV-1 infection. <i>Journal of Infectious Diseases</i> , 2007 , 195, 1452-60	7	115
21	Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes. <i>Journal of Experimental Medicine</i> , 2007 , 204, 3027-36	16.6	356
20	NK cell function in HIV-1 infection. <i>Current Molecular Medicine</i> , 2006 , 6, 621-9	2.5	39

19	Low perforin and elevated SHIP-1 expression is associated with functional energy of natural killer cells in chronic HIV-1 infection. <i>Aids</i> , 2006 , 20, 1549-51	3.5	24
18	Sequential deregulation of NK cell subset distribution and function starting in acute HIV-1 infection. <i>Blood</i> , 2005 , 106, 3366-9	2.2	265
17	Increased natural killer cell activity in viremic HIV-1 infection. <i>Journal of Immunology</i> , 2004 , 173, 5305-11	5.3	104
16	Loss of HIV-1-specific CD8+ T cell proliferation after acute HIV-1 infection and restoration by vaccine-induced HIV-1-specific CD4+ T cells. <i>Journal of Experimental Medicine</i> , 2004 , 200, 701-12	16.6	293
15	CD107a as a functional marker for the identification of natural killer cell activity. <i>Journal of Immunological Methods</i> , 2004 , 294, 15-22	2.5	1005
14	HIV-1-specific cytotoxicity is preferentially mediated by a subset of CD8(+) T cells producing both interferon-gamma and tumor necrosis factor-alpha. <i>Blood</i> , 2004 , 104, 487-94	2.2	111
13	Longitudinal assessment of changes in HIV-specific effector activity in HIV-infected patients starting highly active antiretroviral therapy in primary infection. <i>Journal of Immunology</i> , 2003 , 171, 477-88	5.3	41
12	Preserved recognition of Omicron Spike following COVID-19 mRNA vaccination in pregnancy		1
11	Homologous and Heterologous Vaccine Boost Strategies for Humoral and Cellular Immunologic Coverage of the SARS-CoV-2 Omicron Variant		5
10	Maternal immune response and placental antibody transfer after COVID-19 vaccination across trimester and platforms		1
9	SARS-CoV-2 Viral Load is Associated with Increased Disease Severity and Mortality		10
8	Modified Vaccinia Ankara Based SARS-CoV-2 Vaccine Expressing Full-Length Spike Induces Strong Neutralizing Antibody Response		5
7	An observational study identifying highly tuberculosis-exposed, HIV-1-positive but persistently TB, tuberculin and IGRA negative persons with M. tuberculosis specific antibodies in Cape Town, South Africa		1
6	Outflanking Immunodominance to Target Subdominant Broadly Neutralizing Epitopes		1
5	Antibody against envelope protein from human endogenous retrovirus activates neutrophils in systemic lupus erythematosus		2
4	An intranasal vaccine durably protects against SARS-CoV-2 variants in mice		2
3	Robust IgM responses following vaccination are associated with prevention of Mycobacterium tuberculosis infection in macaques		2
2	Reduced antibody activity against SARS-CoV-2 B.1.617.2 Delta virus in serum of mRNA-vaccinated patients receiving TNF- α inhibitors		1

- 1 Correlates of protection against SARS - CoV -2 infection and COVID-19 disease. *Immunological Reviews*, 11.3 6